VRDN-441

About Viridian Therapeutics

Viridian Therapeutics is a clinical-stage biotech focused on developing novel antibody therapeutics for rare autoimmune conditions, most notably Thyroid Eye Disease (TED). The company's strategy is built on a proprietary antibody engineering platform targeting the neonatal Fc receptor (FcRn) to reduce pathogenic autoantibodies. Its lead programs, VRDN-001 and VRDN-003, are in late-stage development for TED, positioning Viridian as a key player in a market with limited treatment options. The company aims to deliver optimized therapies with potential advantages in dosing, efficacy, and safety.

Therapeutic Areas